news

Company news IP granted Publications

2026-07-20

Risen Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of RP902 for Mild Cognitive Impairment Due to Alzheimer’s Disease

Year:

All 2026 2025 2024 2023 2022 2021 2020

2022-11-22

Congratulations! Risen successfully acquired the identification as the national high-tech enterprise!

Shanghai Zhangjiang R&D Center.

Suzhou Industrial Park R&D Center.

Jiangsu Xuzhou R&D Center

Copyright 2022 Risen(Shanghai) Pharma Tech Co., Ltd. All Rights Reserved 沪ICP备16020731号-1 Design by：yushangweb